PLXP - PLx Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.50
+0.01 (+0.18%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.49
Open5.50
Bid5.20 x 1100
Ask5.45 x 1200
Day's Range5.49 - 5.50
52 Week Range1.00 - 6.44
Volume266
Avg. Volume20,356
Market Cap48.137M
Beta (3Y Monthly)7.05
PE Ratio (TTM)55.00
EPS (TTM)0.10
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents27 days ago

    Edited Transcript of PLXP earnings conference call or presentation 8-Mar-19 1:30pm GMT

    Q4 2018 PLx Pharma Inc Earnings Call

  • GlobeNewswirelast month

    PLx Pharma Inc. Reports Fourth Quarter 2018 Results

    – Company Completes Successful $15 Million Financing – HOUSTON, March 08, 2019 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty.

  • GlobeNewswire2 months ago

    PLx Pharma Inc. to Discuss 2018 Fourth Quarter and Full Year Financial Results on March 8, 2019 Conference Call

    HOUSTON, Feb. 25, 2019 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected.

  • GlobeNewswire2 months ago

    PLx Pharma Inc. Announces Completion of $15 Million Convertible Preferred Stock Financing

    PLx Pharma Inc. (PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced that at its reconvened special meeting of stockholders, held February 19, 2019, the stockholders approved an amendment to the Company’s Amended Certificate of Incorporation to authorize 1,000,000 shares of “blank check” preferred stock (Proposal 1) and the issuance of more than 20% of the Company’s common stock pursuant to a private placement transaction with certain accredited investors and a change of control for purposes of NASDAQ Listing Rule 5635 (Proposal 2). Upon this stockholder approval, the Company has today completed the $15 million convertible preferred stock financing by investment funds affiliated with Park West Asset Management LLC.

  • GlobeNewswire2 months ago

    PLx Pharma Inc. Announces Adjournment of Special Meeting of Stockholders

    PLx Pharma Inc. (PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today that its Special Meeting of Stockholders, held on February 14, 2019 (the “Original Meeting”), was adjourned until February 19, 2019, at 9:00 a.m. Eastern Time (the “Adjourned Meeting”).

  • Benzinga3 months ago

    PLx Pharma's Capital Raise More Dilutive Than Expected, Raymond James Says

    PLx Pharma Inc (NASDAQ: PLXP ) recently raised $15 million in gross proceeds by issuing convertible preferred stock financing. The capital raise is significantly more dilutive than was previously anticipated, ...

  • GlobeNewswire4 months ago

    PLx Pharma Inc. Announces $15 Million Convertible Preferred Stock Financing

    PLx Pharma Inc. (PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced today it has signed a stock purchase agreement with funds affiliated with Park West Asset Management LLC (collectively, "Park West") to purchase 15,000 shares of newly issued Series A Convertible Preferred Stock (“Preferred Stock”), for gross proceeds of $15 million. The Company intends to use the proceeds from the issuance of the Preferred Stock to advance Vazalore to market readiness, and for working capital and general corporate purposes.

  • GlobeNewswire4 months ago

    PLx Pharma Inc. to Present at Biotech Showcase 2019

    HOUSTON, Dec. 18, 2018 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of PLXP earnings conference call or presentation 9-Nov-18 1:30pm GMT

    Q3 2018 PLx Pharma Inc Earnings Call

  • GlobeNewswire5 months ago

    PLx Pharma Inc. Reports Third Quarter 2018 Results

    PLx has identified the alternate supply of a key ingredient for Vazalore HOUSTON, Nov. 09, 2018 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage.

  • GlobeNewswire6 months ago

    PLx Pharma Inc. to Discuss 2018 Third Quarter Financial Results on November 9, 2018 Conference Call

    HOUSTON, Nov. 01, 2018 -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected.

  • Simply Wall St.7 months ago

    Who Really Owns PLx Pharma Inc (NASDAQ:PLXP)?

    Every investor in PLx Pharma Inc (NASDAQ:PLXP) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • ACCESSWIRElast year

    Blog Exposure - Arcturus Initiates Lawsuit against Former CEO Joseph Payne for Misconduct and Violations of Federal Disclosure

    Stock Monitor: PLx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd (NASDAQ: ARCT ) ("Arcturus"). ...